13F Filings History of Paradigm Biocapital Advisors LP

Latest 13F filing: Q1 2026 - 15 May 2026
Latest reported 13F value: $4,894,261,608
Largest 13F holdings: ACLX RVMD NUVL PCVX EWTX GMAB INSM TARS BLTE ERAS CNTA OLMA
+8 more
TERN ORKA APGE SYRE CYTK ABVX TNGX MAZE
Form 13F summary: Paradigm Biocapital Advisors LP Form 13F history summarizes parsed U.S.-listed equity disclosures for this manager.
Form 13F is generally due within 45 days after each calendar quarter ends.
Paradigm Biocapital Advisors LP reported 35 equity holdings with a total reported market value of $4,894,261,608 for Q1 2026. Top reported holdings included ACLX, RVMD, NUVL, PCVX, and EWTX.
Manager signature: David Kim - Chief Operating Officer and Chief Compliance Officer
Manager location: New York, NY

Follow Filing Activity

Follow Paradigm Biocapital Advisors LP with Pro and return when a new 13F portfolio filing changes the record on this page.

Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.

Review Pro alert access Already have an account? Sign in and return here

Holdings Value

Form 13F evidence

Quarterly portfolio filings

SEC-reported 13F quarters for this filer, ordered by the latest accepted filing.

Latest quarter

Q1 2026

Latest value

$4,894,261,608

Quarter delta

+$1,159,326,705

Accepted

15 May 2026, 14:28

Rows shown

1-18 of 18

Quarter	Holdings	SEC-reported value	Bought	Sold	Net	Top Holdings	Form Type	Accepted by SEC
Q1 2026	35	$4,894,261,608	+$1,285,910,373	-$659,906,509	+$626,003,864	ACLX, RVMD, NUVL, PCVX, EWTX	13F-HR	15 May 2026, 14:28
Q4 2025	29	$3,734,934,903	+$555,844,259	-$1,047,576,645	-$491,732,386	NUVL, RVMD, ACLX, GMAB, TARS	13F-HR	17 Feb 2026, 14:01
Q3 2025	33	$3,379,723,926	+$734,475,465	-$411,685,167	+$322,790,298	NUVL, MRUS, ACLX, RVMD, TARS	13F-HR	14 Nov 2025, 13:50
Q2 2025	28	$2,342,122,068	+$431,381,966	-$253,211,643	+$178,170,323	NUVL, ACLX, MRUS, RVMD, TARS	13F-HR	14 Aug 2025, 14:13
Q1 2025	27	$2,172,397,711	+$298,437,072	-$533,162,131	-$234,725,059	NUVL, ACLX, RVMD, ONC, MRUS	13F-HR	15 May 2025, 13:10
Q4 2024	28	$2,874,091,779	+$555,397,277	-$353,818,422	+$201,578,855	NUVL, ACLX, ARGX, RVMD, JANX	13F-HR	14 Feb 2025, 13:24
Q3 2024	31	$2,857,488,790	+$455,316,471	-$661,638,269	-$206,321,798	NUVL, ACLX, ARGX, RVMD, CRNX	13F-HR	14 Nov 2024, 14:14
Q2 2024	35	$2,613,016,030	+$527,292,896	-$563,055,728	-$35,762,832	NUVL, ARGX, ACLX, RVMD, SRPT	13F-HR	14 Aug 2024, 13:09
Q1 2024	34	$2,840,751,736	+$870,007,237	-$323,573,707	+$546,433,530	NUVL, ACLX, ARGX, IRON, CRNX	13F-HR	15 May 2024, 12:57
Q4 2023	29	$2,133,792,483	+$599,973,278	-$288,485,303	+$311,487,975	NUVL, ACLX, ARGX, IRON, LEGN	13F-HR	14 Feb 2024, 13:14
Q3 2023	29	$1,466,160,918	+$480,404,943	-$209,216,693	+$271,188,250	LEGN, ARGX, ACLX, OLMA, NUVL	13F-HR	14 Nov 2023, 12:19
Q2 2023	29	$1,235,711,357	+$384,621,515	-$251,618,328	+$133,003,187	LEGN, INCY, IMCR, ACLX, KRTX	13F-HR	14 Aug 2023, 14:01
Q1 2023	25	$1,055,174,719	+$398,778,371	-$138,658,381	+$260,119,990	BIIB, INCY, LEGN, ARGX, SGEN	13F-HR	15 May 2023, 13:17
Q4 2022	23	$851,901,577	+$250,446,435	-$202,400,251	+$48,046,184	INCY, BIIB, MRTX, HZNP, LEGN	13F-HR	14 Feb 2023, 12:50
Q3 2022	27	$710,089,000	+$239,289,336	-$95,831,220	+$143,458,116	GBT, MRTX, INCY, ASND, LEGN	13F-HR	14 Nov 2022, 12:44
Q2 2022	23	$501,530,000	+$213,556,421	-$85,695,317	+$127,861,104	LEGN, GBT, MRTX, SRRA, INCY	13F-HR	15 Aug 2022, 12:12
Q1 2022	25	$378,175,000	+$170,724,649	-$93,221,753	+$77,502,896	ASND, GBT, ARVN, LEGN, SRRA	13F-HR	16 May 2022, 10:25
Q4 2021	24	$350,154,000	$0	$0	$0	MRTX, ASND, ZNTL, VRDN, ARNA	13F-HR	14 Feb 2022, 09:40